Physician profile
Selina Luger
NPI 1447292982
$122,379.45
in general payments reported to CMS, 2019-2025
20 companies · $25K in 2025
The $25K reported for 2025 was more than what 87% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $5,349 · 2021: $33.36 · 2022: $5,035 · 2023: $38K · 2024: $29K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $41K · Travel and Lodging: $35K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $1,283 · Education: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $40,590.45 |
| Travel and Lodging | $34,853.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,287.00 |
| Food and Beverage | $1,282.52 |
| Education | $717.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $64,113.74 | 2023-2025 | Blincyto, Blincyto |
| Daiichi Sankyo INC. | $16,293.67 | 2019-2025 | Vanflyta |
| Astrazeneca Pharmaceuticals LP | $11,397.68 | 2025 | |
| Pfizer INC. | $7,282.00 | 2019 | |
| Abbvie INC. | $5,252.25 | 2020-2025 | |
| Jazz Pharmaceuticals INC. | $4,578.36 | 2019 | |
| Celgene Corporation | $3,127.36 | 2019 | |
| Astrazeneca Uk Limited | $2,460.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,152.50 | 2022 | |
| Agios Pharmaceuticals, INC. | $2,039.35 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $2,025.00 | 2023 | Scemblix |
| Eli Lilly Export S.A. Puerto Rico Branch | $1,087.29 | 2020 | |
| Geron Corporation | $239.29 | 2025 | Imetelstat, Rytelo |
| Astellas Pharma US INC | $234.70 | 2022-2024 | Xospata |
| Eli Lilly and Company | $45.80 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $33.36 | 2021 | |
| Shorla Oncology INC. | $17.10 | 2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selina Luger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.